Scientists unlock why amino acids make medicines last longer

Insulin, vaccines, and gene therapies are among medicine's most powerful tools — but they're fragile. Proteins, the molecules these drugs are made from, have a tendency to clump together and break down, especially during manufacturing and storage. When that happens, the medicine loses potency. For decades, pharmaceutical makers knew that adding certain amino acids helped stabilize these drugs, but they didn't really understand why.

Now they do. An international team of researchers from MIT, Swiss university EPFL, and China's Southern University of Science and Technology has published a theory that explains the mechanism — and it could reshape how we design protein-based medicines going forward.

How proteins fall apart (and how to stop it)

Think of a protein molecule as a ball covered in Velcro patches. In the body's fluids, these proteins naturally stick to each other, forming clumps. When they clump, less of the protein's surface is exposed to interact with water and the rest of the bloodstream — which means the medicine can't do its job as effectively.

Amino acids, it turns out, act like loose bits of Velcro floating around in solution. They attach to those sticky patches on the protein balls, blocking them from clumping together. The effect is cumulative: many weak interactions add up to strong stabilization.

MIT's Alfredo Alexander-Katz, a theorist who led the work, explains it another way. "The cell makes proteins and then breaks them," he says. "Free amino acids floating in the cell have an important effect on how proteins interact, helping maintain balance and stability."

The team tested their theory against experimental data and found it matched. They also discovered that different combinations of molecules can produce the same stabilizing effect — opening the door to customized formulations for different drugs.

From theory to insulin doses

The implications are practical and immediate. In experiments, the team added an amino acid called proline to insulin. The result: insulin became twice as effective in the bloodstream. That means diabetics could need fewer injections while getting the same therapeutic benefit.

Because the amino acids being used are already approved for medical use, there's no regulatory barrier to moving this into real-world application quickly. "This could move more quickly into the real world than traditionally," Alexander-Katz says.

The findings matter because biologics — medicines derived from living organisms — are becoming central to how we treat disease. Insulin, vaccines, monoclonal antibodies, and gene therapies all fall into this category. Being able to stabilize them at higher concentrations while maintaining shelf life has been a persistent challenge. A rational, theory-driven approach to solving it could accelerate development of new therapies across multiple diseases.

The research was published in Nature, and the team's hope is that pharmaceutical companies will adopt these principles to design better, longer-lasting medicines from the ground up.